The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R.sup.1, and R.sup.2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. ##STR00001##

The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R.sup.1, and R.sup.2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. ##STR00001##

Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/or prophylaxis of proliferative diseases, including cancer, and more specifically, pancreatic cancer.

Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/or prophylaxis of proliferative diseases, including cancer, and more specifically, pancreatic cancer.

A composite amine absorbent to absorb at least one of CO.sub.2 and H.sub.2S in a gas includes: a chain monoamine; a diamine; a cyclic compound represented by the following chemical formula: ##STR00001##
where R.sup.1: any one of hydrogen, a hydrocarbon group having a carbon number of 1 to 4, and a hydroxyalkyl group, R.sup.2: oxygen or NR.sup.3, and R.sup.3: any one of hydrogen, a hydrocarbon group having a carbon number of 1 to 4, and a hydroxyalkyl group; and water.

Provided are compounds of the Formula (IIB): ##STR00001##
or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Cleavable crosslinkers of Formula (I) useful reagents in biochemical drug research and development such as antibody drug conjugates are disclosed. ##STR00001##